Glenmark Pharmaceuticals Limited (NSE: GLENMARK), ISIN INE935A01035 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
GLENMARK last traded at ₹2261.95 (+3.53%), with a 52-week range of ₹1794.00 to ₹2471.05 (as of 30 Jul 2026).
Shareholding as of Jun 2026: promoters 46.65%, FIIs 20.89%, DIIs 18.60%, mutual funds 16.76%.
EquiSense Score (ECS): 75/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.